The Clardy Lab is a research laboratory with clinical specialization and research focus in the field of autoimmune neurology, which encompasses the evaluation and management of both autoimmune and paraneoplastic disorders of the nervous system. The spectrum of autoimmune and paraneoplastic neurological disorders intersects all traditional neurology subspecialties, including movement disorders, epilepsy, behavioral/cognitive, neuromuscular, autonomic, demyelinating, and neuro-oncologic. Our laboratory is also the leading protocol and scientific team of an NIH U01 grant (via the NeuroNEXT Clinical Trials Network) to fund the ExTINGUISH Trial—the first prospective, international, and randomized clinical trial for NMDA receptor encephalitis, at 20 US sites and 2 European sites, with enrollment beginning early 2022. Our research focuses on a spanning spectrum from basic science to the applied population as we are devoted to understanding the effects of antibody-mediated disorders of the nervous system, both autoimmune and paraneoplastic. Areas of Focus include Autoimmune Encephalitis, Neurosarcoidosis, Neuromyelitis Optica spectrum disorder (NMOSD), Myelin Oligodendrocyte Glycoprotein antibody disease (MOGAD), Stiff Person Syndrome, Myelopathy/Transverse Myelitis, and central nervous system complications of rheumatologic disease. The Clardy lab is a multidisciplinary team consisting of 1 early-stage faculty, one clinical research manager, two biostatisticians, one clinical research coordinator, one data management specialist, two clinical fellows, one research fellow, two neurology residents, one Ph.D. student, one medical student, and one high school student.
Project survey design, and learning how to conduct research procedures.